I came across NetEase (NASDAQ:NTES) in early 2013, when it was starting to become a major player in the Chinese mobile game industry. At first, I was a bit skeptical about their future growth and valuation. Video game companies are sometimes “one-hit wonders”, and decline after their top sellers lose popularity. But NetEase is an exception. After watching it for a few months, I decided....More>>>
It’s been a long decade for Yahoo (Nasdaq: YHOO). The search and tech company has seen its stock rise just 10% over the past 10 years.
This comes after years of battling activist investors, a carousel of CEOs, and a declining business. The saving grace has been Alibaba (Nasdaq: BABA), where Yahoo has a 15% stake in the company. The success of Alibaba has helped overshadow Yahoo’s....More>>>
Intrexon (XON) has made a small yet strategic acquisition in buying GenVec (GNVC); with the purchase, XON gets AdenoVerse, a platform of adenovirus vectors for delivering drugs and vaccines that dovetails nicely with its existing suite of gene therapy technologies, suggests John McCamant, editor of The Medical Technology Stock Letter.
The ability to increase the payloads of viral vectors....More>>>
Gainers Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate. Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination....More>>>
Therapix Biosciences (NASDAQ:TRPX) received an initiation of coverage from Laidlaw & Company analyst Francois Brisebois who gave the company a Buy rating and a $18.00 price target. Therapix’s lead drug is an FDA approved dronabinol, which is a biosynthetic form of THC. The company’s strategy is to repurpose, reposition and improve the FDA approved cannabinoid for various....More>>>
Wells Fargo (WFC) has come a long way since its account-opening scandal–enough that it makes you wonder if that scandal has been forgotten on Wall Street. Not Argus analyst Stephen Biggar, who cut Wells Fargo today, arguing that the scandal remains an overhang for the banking giant following its earnings miss last week:
Agence France-Presse/Getty Images
We are downgrading....More>>>
Why should investors like marijuana stocks? For some, the rationale might be the enormous market potential. For others, it could be simply that many marijuana stocks have soared over the last year or so.
There are plenty of reasons for investors to like three marijuana stocks in particular — GW Pharmaceuticals (NASDAQ:GWPH), Insys Therapeutics (NASDAQ:INSY), and Aphria (NASDAQOTH:APHQF).....More>>>
Donald Trump’s comments yesterday about the drug industry when he stated that drug companies were “getting away with murder” tanked biotech stocks and the general indexes. Investors in this space must be worried in the event that Trump gains some traction in this sector and records some wins. At present, he is like a dog with a bone. In the automotive sector, for example, he is....More>>>
Verizon Communications (VZ) tumbled to the bottom of the S&P 500 today after its earnings fell short of analyst forecasts.
Verizon Communicationsdropped 4.4% to $50.12 today, while the S&P 500 rose 0.7% to 2,280.07.
BTIG’s Walter Piecyk and Joseph Galone wonder if Verizon’s “network advantage over.” They explain why:
German banking giant Deutsche Bank said Friday it has agreed toa $7.2 billion settlement with the U.S. Justice Department over its marketing and sales of mortgage-backed bonds risky securities that helped start the global financial crisis.
Under the deal, which isnt yet final, the bank agreed to pay $3.1 billion in fines and $4.1 billion in compensation through such measures as easing loan....More>>>